GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Akums Drugs and Pharmaceuticals AKUMS.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

765.85

+4.20%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹43.59bn

FY2022FY2026

Net income

₹2.55bn

FY2022FY2026

Free cash flow

₹9.80bn

FY2022FY2026

Shareholders' equity

₹33.13bn

FY2022FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022
Revenue₹43.59bn₹40.71bn₹40.20bn₹34.75bn₹36.47bn
Operating income₹4.76bn₹3.76bn₹3.60bn₹1.91bn₹3.22bn
Net income₹2.55bn₹3.38bn−₹40.4m₹948.5m−₹2.53bn
Diluted earnings per share16.6722.09-0.266.20-16.49

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022
Total assets₹54.47bn₹41.13bn₹35.16bn₹32.67bn₹30.69bn
Cash and short-term investments₹16.81bn₹5.82bn₹2.88bn₹1.50bn₹1.03bn
Total liabilities₹21.16bn₹10.50bn₹27.96bn₹25.43bn₹24.44bn
Debt₹1.57bn₹882.1m₹5.65bn₹6.19bn₹3.95bn
Shareholders' equity₹33.13bn₹30.47bn₹7.09bn₹7.17bn₹6.22bn
Shares outstanding153m153m153m153m153m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022
Cash from operations₹12.11bn₹4.65bn₹4.98bn₹1.77bn₹318.5m
Capital spending−₹2.31bn−₹2.72bn−₹3.11bn−₹3.29bn−₹2.58bn
Free cash flow₹9.80bn₹1.93bn₹1.87bn−₹1.52bn−₹2.26bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹11.67bn₹11.58bn₹11.60bn₹10.18bn₹10.24bn₹10.08bn₹10.10bn₹10.33bn
Operating income₹1.34bn₹1.12bn₹1.07bn₹566.1m₹920.5m₹574.0m₹768.5m₹863.2m
Net income₹1.00bn₹846.1m₹663.2m₹407.8m₹634.8m₹1.48bn₹651.8m₹652.1m
Diluted earnings per share6.535.534.332.664.159.644.264.26
Cash from operations———₹11.52bn—₹3.94bn——
Capital spending———−₹1.12bn—−₹1.22bn——
Free cash flow———₹10.40bn—₹2.72bn——
Total assets—₹54.47bn—₹51.59bn—₹41.13bn—₹42.70bn
Cash and short-term investments—₹16.81bn—₹16.78bn—₹5.82bn—₹8.24bn
Debt—₹805.9m—₹150.8m—₹208.8m—₹4.65bn
Shareholders' equity—₹33.13bn—₹31.49bn—₹30.47bn—₹28.33bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.6%——
Operating income35.5%——
Net income39.1%——

Valuation history

At each fiscal year end

FY2026FY2025FY2024
Price to earnings44.920.4-2420.8
Price to sales2.81.72.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.